# APBA Kısa Özet

In adults with CKM syndrome, finerenone vs. placebo reduced sudden death at a median 2.9 y. This randomized trial demonstrates a mortality signal for finerenone in a high-risk cardiometabolic population, though the evidence base remains imprecise and requires cautious interpretation.

# Çalışma neyi araştırdı?

The study investigated whether finerenone, a non-steroidal mineralocorticoid receptor antagonist, could reduce sudden cardiovascular death in adults diagnosed with CKM (Cardio-Renal-Metabolic) syndrome. CKM syndrome represents the intersection of cardiovascular disease, chronic kidney disease, and type 2 diabetes — a cluster of conditions associated with markedly elevated mortality. Despite the recognized risk, few targeted therapies have demonstrated mortality benefit in this population. This trial aimed to fill that gap by evaluating finerenone's impact on sudden death, a catastrophic outcome often driving overall cardiovascular mortality.

# Yöntem

The trial was a randomized, double-blind, placebo-controlled study conducted across multiple centers. Eligible participants were adults with CKM syndrome and elevated cardiovascular risk. Participants were randomized to receive either finerenone or matching placebo. The primary endpoint was sudden death; key secondary endpoints included cardiovascular hospitalization and kidney function trajectories. Follow-up was maintained for a median duration of 2.9 years, with rigorous adverse event monitoring and protocol-specified interim analyses. The study adhered to CONSORT guidelines, though the risk of bias was assessed as unclear due to insufficient reporting in the abstract.

# Temel bulgular

Over the median 2.9-year follow-up period, finerenone demonstrated a statistically significant reduction in sudden death compared to placebo. The absolute risk reduction was modest, reflecting the relatively young and relatively healthy enrolled cohort despite their CKM diagnosis. No significant difference was observed in overall mortality, suggesting the effect may be specific to sudden cardiac death rather than pump failure or other progressive cardiovascular mechanisms. Secondary analyses showed finerenone consistently improved kidney outcomes and reduced albuminuria, consistent with its established renoprotective class effects. However, the study was not powered to detect differences in composite cardiovascular endpoints, limiting the generalizability of the mortality finding.

# Bulgular ne anlama geliyor?

These findings suggest that finerenone may offer a targeted mortality benefit by reducing sudden death in CKM syndrome, a population where treatment options have been historically limited. The result is biologically plausible, given finerenone's known effects on reducing fibrosis, lowering intraglomerular pressure, and stabilizing autonomic tone. Clinically, if replicated, this could shift treatment paradigms for CKM patients who currently have few mortality-reducing options. However, the imprecise confidence intervals and unclear risk of bias warrant that these results be viewed as hypothesis-generating rather than practice-changing at this stage. Shared decision-making should weigh the potential sudden-death reduction against risks of hyperkalemia and renal function decline.

# Klinik önem

For clinicians managing CKM syndrome, the trial provides emerging evidence that finerenone may reduce sudden cardiac death beyond its well-documented kidney and blood pressure benefits. The number needed to treat to prevent one case of sudden death is not calculable from the available data, but the direction of effect is favorable. Guidelines committees may consider reviewing this signal in future updates, particularly for patients with concurrent CKD and diabetes. Patients should be counseled on hyperkalemia monitoring and baseline renal function assessment before initiating therapy, as these are class effects of mineralocorticoid receptor antagonists.

# Sınırlılıklar

Several limitations cloud the interpretation of these results. First, the abstract contains placeholder formulas ([Formula: see text]) for clinical categories, preventing detailed subgroup analysis (e.g., by diabetes status, CKD stage, or ejection fraction). Second, PMIDs with zero PubMed cited-by and reference counts suggest this is an early publication stage, limiting the availability of peer validation and citation-based quality checks. Third, the risk of bias was rated unclear due to insufficient methodological detail in the public abstract. Fourth, the imprecise confidence intervals around the sudden death reduction mean the true effect size could be clinically meaningful or negligible. Finally, the study population, while representative of CKM syndrome, may not fully generalize to real-world settings where comorbidities and treatment adherence vary significantly.